Balyasny Asset Management
RLMD icon

Balyasny Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Balyasny Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.76M Sell
252,457
-295,397
-54% -$1.4M ﹤0.01% 1842
2025
Q4 		$2.65M Buy
+547,854
New +$1.84M ﹤0.01% 1728
2024
Q2 		– Sell
-12,322
Closed -$57.3K – 3020
2024
Q1 		$57.3K Buy
+12,322
New +$59.4K ﹤0.01% 2522
2022
Q4 		– Sell
-307,314
Closed -$11.4M – 3165
2022
Q3 		$11.4M Buy
307,314
+68,793
+29% +$1.91M 0.03% 628
2022
Q2 		$4.53M Buy
+238,521
New +$5.2M 0.01% 989

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Balyasny Asset Management's RLMD Position: Q1 2026 in Review

Balyasny Asset Management reduced its Relmada Therapeutics (RLMD) stake by 54% in Q1 2026, selling an estimated $1.4M and leaving 252,457 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1842.

Balyasny Asset Management first reported a position in RLMD in Q2 2022 and has held it in 5 quarters since. The position peaked at $11.4M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Balyasny Asset Management held 252,457 shares of Relmada Therapeutics worth $1.76M as of Q1 2026.
  • Balyasny Asset Management sold 295,397 Relmada Therapeutics shares in Q1 2026, an estimated $1.4M.
  • Relmada Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1842 holding.
  • Balyasny Asset Management first reported a position in Relmada Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • Balyasny Asset Management's Relmada Therapeutics position peaked at $11.4M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.